CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Organon & Co.

OGN
$5.30B
Mid Cap
NASDAQPharmaceutical PreparationsPharmaceuticals🇺🇸North AmericaJERSEY CITY10.0K employees

Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.

Website

Drugs in Pipeline

55

Phase 3 Programs

43

Upcoming Catalysts

0

Next Catalyst

None scheduled

Market Overview

Stock performance and key metrics

OGN News
Catalyst Timeline

0 upcoming, 1 past

No catalysts found.

Drug Pipeline

Asenapine - Open Label

Phase 3

Schizophrenia

ezetimibe (+) simvastatin

Phase 3

Hyperlipidemia

Corifollitropin alfa

Phase 3

In Vitro Fertilization

desloratadine

Phase 3

Dermatitis, Atopic

MK0462, rizatriptan benzoate / Duration of Treatment: 1day

Phase 3

Migraine

Ezetimibe

Phase 3

Hypercholesterolemia

Radiopaque Etonogestrel Implant

Phase 3

Contraception

rizatriptan benzoate

Phase 3

Migraine Headache

Ezetimibe + Atorvastatin

Phase 3

Hypercholesterolemia

Montelukast 10 mg/loratadine 10 mg

Phase 3

Allergic Rhinitis

ezetimibe/simvastatin

Phase 3

Hypercholesterolemia

losartan potassium

Phase 3

Hypertension

MK0476, montelukast sodium / Duration of Treatment: 12 Weeks

Phase 3

Asthma

mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID

Phase 3

Asthma

montelukast sodium

Phase 3

Seasonal Allergic Rhinitis

atorvastatin

Phase 3

Hypercholesterolemia

MK0663, Etoricoxib / Duration of Treatment : 12 Weeks

Phase 3

Recurrent Low Back Pain

A-Phase: tirofiban; Z-Phase simvastatin

Phase 3

Acute Coronary Syndrome

MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet

Phase 3

Osteoporosis

Radiopaque Implanon

Phase 3

Contraception

MK-0653, ezetimibe

Phase 3

Hypercholesterolaemia

ezetimibe 10 mg

Phase 3

Hypercholesterolemia

losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])

Phase 3

Hypertension

NOMAC-E2

Phase 3

Contraception

olanzapine

Phase 3

Schizophrenia

MK0653, ezetimibe

Phase 3

Lipid Metabolism, Inborn Errors

Desloratadine (Clarinex)

Phase 3

Allergic Rhinitis

MK0476, montelukast sodium / Duration of Treatment: 1 Year

Phase 3

Asthma, Bronchial

tibolone

Phase 3

Sexual Dysfunction

Desloratadine 5 mg

Phase 3

Eczema

tapinarof cream, 1%

Phase 3

Plaque Psoriasis

phenylephrine

Phase 3

Rhinitis, Allergic, Seasonal

5-mg Desloratadine

Phase 3

Rhinitis, Allergic, Seasonal

asenapine

Phase 3

Schizophrenia

Mometasone Furoate Nasal Spray (MFNS)

Phase 3

Nasal Polyps

Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI

Phase 3

Asthma

MK0653, ezetimibe / Duration of Treatment: 6 Weeks

Phase 3

Hypercholesterolemia

MK0653, ezetimibe / Duration of Treatment: 30 Weeks

Phase 3

Diabetes Mellitus, Type 2

DRSP-EE

Phase 3

Contraception

Part I - etoricoxib 60 mg

Phase 3

Spondylitis, Ankylosing

Mometasone furoate/formoterol (MF/F) MDI

Phase 3

Asthma

Haloperidol

Phase 3

Schizophrenia

MK0663, etoricoxib

Phase 3

Rheumatoid Arthritis

Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg

Phase 2

Asthma

Nomegestrol acetate (NOMAC)

Phase 2

Contraception

Desloratadine 2.5 mg

Phase 2

Post-nasal Drip

E6005

Phase 2

Atopic Dermatitis

E6005 ointment (vehicle)

Phase 2

Atopic Dermatitis

Org 36286 (corifollitropin alfa)

Phase 2

In Vitro Fertilization

MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)

Phase 2

Osteoarthritis

MK-0476, montelukast sodium

Phase 2

Bronchiolitis

etoricoxib

Phase 2

Rheumatoid Arthritis

MFNS

Phase 2

Acute Rhinosinusitis

Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)

Phase 2

Dysmenorrhea

Mometasone furoate

Phase 2

Rhinitis, Allergic, Perennial

Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply